Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cellectis S.A. ADR
(NQ:
CLLS
)
2.506
+0.016 (+0.63%)
Streaming Delayed Price
Updated: 3:36 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cellectis S.A. ADR
< Previous
1
2
Next >
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
April 22, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
April 10, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
April 08, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
January 16, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
November 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
November 15, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
November 06, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
November 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
November 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
November 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
October 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
October 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
August 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
August 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
July 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
June 28, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
June 09, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
June 05, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
May 31, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
May 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
May 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
May 11, 2023
BALLI-01 (evaluating UCART22) abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
May 04, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
April 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
April 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.